Case Report: Targeted treatment by fluoxetine/norfluoxetine of a KCNC2 variant causing developmental and epileptic encephalopathy

Authors

• Ping Li, Washington University School of Medicine in St. Louis
• Alice Butler, Washington University School of Medicine in St. Louis
• Yu Zhou, Washington University School of Medicine in St. Louis
• Karl L Magleby, University of Miami
• Christina A Gurnett, Washington University School of Medicine in St. Louis
• Lawrence Salkoff, Washington University School of Medicine in St. Louis

Journal

Frontiers in Pharmacology

Publication Date

1-1-2024

Volume

15

First Page

1528541

Document Type

Open Access Publication

DOI

10.3389/fphar.2024.1528541

Rights and Permissions

Li P, Butler A, Zhou Y, Magleby KL, Gurnett CA and Salkoff L (2025) Case Report: Targeted treatment by fluoxetine/norfluoxetine of a KCNC2 variant causing developmental and epileptic encephalopathy. Front. Pharmacol. 15:1528541. doi: 10.3389/fphar.2024.1528541 © 2025 Li, Butler, Zhou, Magleby, Gurnett and Salkoff. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Recommended Citation

Li, Ping; Butler, Alice; Zhou, Yu; Magleby, Karl L; Gurnett, Christina A; and Salkoff, Lawrence, "Case Report: Targeted treatment by fluoxetine/norfluoxetine of a KCNC2 variant causing developmental and epileptic encephalopathy." Frontiers in Pharmacology. 15, 1528541 (2024).
https://digitalcommons.wustl.edu/oa_4/7484

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.